Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Goldman Sachs analyst Andrea Newkirk reinstates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and announces $15 price target.
Goldman Sachs analyst Andrea Newkirk reinstates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and announces $15 price target.